Viridian Therapeutics, Inc.\DE (VRDN) Net Equity Issued and Repurchased (2014 - 2025)

Viridian Therapeutics, Inc.\DE's Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $63.1 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased rose 660.59% year-over-year to $63.1 million; the TTM figure through Mar 2026 stood at $72.8 million (up 1485.12% YoY), while the FY2025 annual figure was $63.1 million, up 152.57% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $63.1 million, up from $9.8 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $63.1 million in Q4 2025, with the low at -$11.3 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $19.7 million (2022), against an average of $20.9 million.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased sank 173.81% in 2024, then soared 820.19% in 2025.
• Viridian Therapeutics, Inc.\DE's Net Equity Issued and Repurchased stood at $32.4 million in 2021, then dropped by 25.31% to $24.2 million in 2022, then slumped by 36.94% to $15.3 million in 2023, then slumped by 173.81% to -$11.3 million in 2024, then soared by 660.59% to $63.1 million in 2025.
• Business Quant data shows VRDN's Net Equity Issued and Repurchased at $63.1 million in Q4 2025, $9.8 million in Q3 2025, and -$143000.0 in Q2 2025.